XML 13 R2.htm IDEA: XBRL DOCUMENT v3.20.2
Balance Sheets - USD ($)
Sep. 30, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 8,840,607 $ 1,858
Grant receivable 424,952 735,075
Prepaid expenses and other current assets 136,442 10,579
Total current assets 9,402,001 747,512
Long-term assets:    
Deferred offering costs 0 369,595
Total long-term assets   369,595
Total assets 9,402,001 1,117,107
Current liabilities:    
Accounts payable 139,778 1,233,877
Accrued expenses 141,280 776,871
Total current liabilities 281,058 2,010,748
Long-term liabilities:    
Derivative liability   106,000
Convertible promissory notes, net of unamortized deferred financing fees of $7,431 and debt discount of $22,762 at December 31, 2019   499,807
Total long-term liabilities   605,807
Total liabilities 281,058 2,616,555
Commitments and contingencies (Note 8)
Stockholders’ equity (deficit):    
Preferred stock - $0.0001 par value, 2,000,000 and 0 shares authorized at September 30, 2020 and December 31, 2019, respectively
Common stock - $0.0001 par value, 35,000,000 and 10,150,000 shares authorized at September 30, 2020 and December 31, 2019, respectively, and 6,871,608 and 282,614 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively 687 28
Additional paid-in capital 21,654,718 200,600
Accumulated deficit (12,534,462) (8,777,028)
Total stockholders’ equity (deficit) 9,120,943 (8,576,400)
Total liabilities and stockholders’ equity (deficit) 9,402,001 1,117,107
Series A Redeemable convertible preferred stock    
Long-term liabilities:    
Redeemable convertible preferred stock 0 6,509,303
Series A-1 Redeemable convertible preferred stock    
Long-term liabilities:    
Redeemable convertible preferred stock $ 0 $ 567,649